Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

Rituximab‐containing induction followed by autologous stem cell transplantation (ASCT) is the standard first‐line treatment for young mantle cell lymphoma patients. However, most patients relapse after ASCT. We investigated in a randomised phase II study the outcome of a chemo‐immuno regimen and ASC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Haematol
Autors principals: Doorduijn, Jeanette K., Zijlstra, Josee M., Lugtenburg, Pieternella J., Kersten, Marie Josee, Böhmer, Lara H., Minnema, Monique C., MacKenzie, Marius A., van Marwijk Kooij, Rien, de Jongh, Eva, Snijders, Tjeerd J.F., de Weerdt, Okke, van Gelder, Michel, Hoogendoorn, Mels, Leys, Rineke B.L., Kibbelaar, Robby E., de Jong, Daphne, Chitu, Dana A., Van’t Veer, Mars B., Kluin‐Nelemans, Hanneke C.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Haematological Malignancy ‐ Clinical
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7496560/
https://ncbi.nlm.nih.gov/pubmed/32150297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16567
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars